Shennon Biotechnologies Raises $12M Series A for Solid Tumor Immunotherapies

Shennon Biotechnologies Closes $12M Series A

Shennon Biotechnologies, a San Francisco-based biotechnology company developing precision immunotherapies for solid tumors, has raised $12 million in Series A funding. The round was announced on September 14, 2026.

What the Company Does

Founded in 2021, ShennonBio operates an integrated discovery engine that combines several capabilities:

• Target identification
• Ultra-high-throughput single-cell functional screening
• Computational binder design
• AI-driven safety prediction

The company's TCELERATOR platform profiles more than 10 million single-cell interactions at once. Its pipeline of antibody- and TCR-based T-cell engager programs targets small cell lung cancer, ovarian cancer, and hepatocellular carcinoma.

ShennonBio operates laboratory space near UCSF Mission Bay.

Leadership

The company is led by CEO Cyril Konto alongside founder Li Sun, who serves as President and Chief Technology Officer.

The Round

• Round type: Series A
• Amount: $12,000,000 USD
• Date: September 14, 2026
• Investors: Future Ventures, AV8 Ventures, NextGen Venture Partners, DCVC, Saras Capital, Foundation Capital, Samos Investments, Atypical Ventures

No lead investor was disclosed for the round.

Why It Matters

ShennonBio sits at the intersection of single-cell screening and computational design, two areas that have become central to the search for next-generation immunotherapies. The company's focus on solid tumors addresses a category that has historically lagged behind hematological cancers in response to immunotherapy. Its T-cell engager programs span three tumor types, and the TCELERATOR platform's throughput claim — profiling more than 10 million single-cell interactions at once — positions the company around scale in functional screening.

Acquisition Context

For acquirers and strategic partners, ShennonBio represents an early-stage but platform-oriented asset. The company combines a discovery engine with a defined pipeline, which is a structure that can be attractive to larger biopharma players seeking to in-source screening and binder design capabilities. The Series A funding provides capital to advance both the platform and the pipeline toward the clinic.

Key considerations for potential acquirers include the breadth of the pipeline across small cell lung cancer, ovarian cancer, and hepatocellular carcinoma, the dual antibody- and TCR-based approach, and the leadership team's combination of operational and scientific experience. The company's location near UCSF Mission Bay places it within a dense life sciences ecosystem.

Summary

Shennon Biotechnologies has raised $12 million in Series A funding to support its precision immunotherapy programs for solid tumors. The round, announced September 14, 2026, included participation from Future Ventures, AV8 Ventures, NextGen Venture Partners, DCVC, Saras Capital, Foundation Capital, Samos Investments, and Atypical Ventures.